London, 22 July 2015: Technavio, the independent tech-focused global research firm, has published a report on the global Ischemic heart disease drugs market 2015-2019, which is expected to post a CAGR of 3.61% during the forecast period of 2014-2019.
“Different vendors in the market are increasingly forming strategic alliances and engaging in mergers and acquisitions to increase their market share,” says Faisal Ghaus, Vice President of Technavio.
“Such collaborations help in the increased penetration of the drug in a particular market and thereby help in the increased sales. This is expected to fuel the growth of the market.”
Key Market Drivers
- Increase in Patient Population
- Increase in Aging Population
- Sedentary Lifestyle
- Rise in Obese Population
- High Prevalence of Chronic Conditions
Key Market Trends
- Increase in Awareness
- Strategic Alliances
- Increased R&D
Key Market Vendors
- AstraZeneca plc
- Bayer AG
- Eli Lilly and Co.
- Novartis AG
- Pfizer Inc.
- Sanofi SA
To define the market circumstances in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
